Theriva Biologics announces VCN-01 Phase 1 HNSCC data showing median OS up to 17.3 months

Theriva Biologics, Inc.

Median OS 10.3-17.3 months across three arms in heavily pre-treated, immunotherapy-refractory HNSCC patients.
Median PFS 1.6-3.7 months; best PFS (3.7 mo) in sequential low-dose VCN-01 arm (Arm II LD).
Biomarker data confirms VCN-01 mechanism: increased PH20, viral replication, CD8+ T cell infiltration, PD-L1 upregulation.
Results published online in Clinical Cancer Research; trial NCT03799744 enrolled 20 patients.
Data suggest VCN-01 can resensitize refractory tumors to checkpoint inhibitor durvalumab.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.